全文获取类型
收费全文 | 646篇 |
免费 | 20篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 21篇 |
妇产科学 | 18篇 |
基础医学 | 42篇 |
口腔科学 | 2篇 |
临床医学 | 43篇 |
内科学 | 60篇 |
皮肤病学 | 19篇 |
神经病学 | 12篇 |
特种医学 | 5篇 |
外国民族医学 | 1篇 |
外科学 | 11篇 |
综合类 | 158篇 |
预防医学 | 50篇 |
药学 | 161篇 |
中国医学 | 35篇 |
肿瘤学 | 32篇 |
出版年
2024年 | 1篇 |
2023年 | 2篇 |
2021年 | 2篇 |
2020年 | 8篇 |
2019年 | 14篇 |
2018年 | 16篇 |
2017年 | 10篇 |
2016年 | 16篇 |
2015年 | 14篇 |
2014年 | 27篇 |
2013年 | 38篇 |
2012年 | 23篇 |
2011年 | 42篇 |
2010年 | 49篇 |
2009年 | 49篇 |
2008年 | 36篇 |
2007年 | 46篇 |
2006年 | 51篇 |
2005年 | 41篇 |
2004年 | 25篇 |
2003年 | 25篇 |
2002年 | 20篇 |
2001年 | 17篇 |
2000年 | 10篇 |
1999年 | 14篇 |
1998年 | 5篇 |
1997年 | 7篇 |
1996年 | 8篇 |
1995年 | 3篇 |
1994年 | 2篇 |
1993年 | 4篇 |
1992年 | 3篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 3篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 2篇 |
1985年 | 7篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 4篇 |
1981年 | 6篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1976年 | 1篇 |
排序方式: 共有671条查询结果,搜索用时 15 毫秒
61.
Hideto?KamedaEmail author Koichi?Amano Naoya?Sekiguchi Hirofumi?Takei Hiroe?Ogawa Hayato?Nagasawa Tsutomu?Takeuchi 《Modern rheumatology / the Japan Rheumatism Association》2004,14(6):442-446
Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan,
MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at
a dosage of no more than 8 mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether
it is comparable to that in Western countries, where 15–20 mg/week of MTX is used, as well as to elucidate the factors associated
with the favorable response to MTX. Around 8 mg/week of MTX was effective in half of the RA patients in the current study,
and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Some
of the patients who had a poor response to MTX showed an improvement with the addition of bucillamine or prednisolone. For
the remaining patients, an increase in the MTX dosage to more than 8 mg/week or the use of biologics such as the anti-tumor
necrosis factor (TNF)-α monoclonal antibody may be required. 相似文献
62.
Murata K Yasuda T Ito H Yoshida M Shimizu M Nakamura T 《Modern rheumatology / the Japan Rheumatism Association》2006,16(1):14-19
To determine the potential contribution of intermittent low-dose methotrexate (MTX) treatment (2–8 mg/week) to postoperative
complications, we studied 122 patients with rheumatoid arthritis (RA) who had 201 surgical procedures. The patients with treatment
with MTX were allocated to two groups: those who continued MTX (group A, 77 procedures) and those who discontinued MTX more
than 1 week (group B, 21 procedures). The patients who had no treatment with MTX were allocated to group C (103 procedures).
The incidence of postoperative infection, poor wound healing, and flare-up of RA was compared between the three groups. Postoperative
infection occurred in 3.9%, 4.8%, and 3.9% in groups A, B, and C, respectively. Poor wound healing was experienced in 1.3%,
9.5%, and 7.8% in groups A, B, and C, respectively. At 4 weeks postoperatively, 3.9%, 14.3%, and 6.8% of flares were seen
in groups A, B, and C, respectively. No significant difference was found in the patients with or without perioperative use
of MTX. From these results, it is unlikely that continuation of intermittent low-dose MTX treatment increases the risk of
postoperative complications in patients with RA. Continued treatment with MTX during perioperative period could suppress disease
flares, especially in severe RA patients. 相似文献
63.
Laleman W Van Landeghem L Van der Elst I Zeegers M Fevery J Nevens F 《Gastroenterology》2007,132(2):709-719
BACKGROUND & AIMS: We studied whether administration of nitroflurbiprofen (HCT-1026), a cyclooxygenase inhibitor with nitric oxide (NO)-donating properties, modulates the increased intrahepatic vascular tone in portal hypertensive cirrhotic rats. METHODS: In vivo hemodynamic measurements (n = 8/condition) and evaluation of the increased intrahepatic resistance by in situ perfusion (n = 5/condition) were performed in rats with thioacetamide-induced cirrhosis that received either nitroflurbiprofen (45 mg/kg), flurbiprofen (30 mg/kg, equimolar concentration to nitroflurbiprofen), or vehicle by intraperitoneal injection 24 hours and 1 hour prior to the measurements. Additionally, we evaluated the effect of acute administration of both drugs (250 micromol/L) on the intrahepatic vascular tone in the in situ perfused cirrhotic rat liver (endothelial dysfunction and hyperresponsiveness to methoxamine) and on hepatic stellate cell contraction in vitro. Typical systemic adverse effects of nonsteroidal anti-inflammatory drugs, such as gastrointestinal ulceration, renal insufficiency, and hepatotoxicity, were actively explored. RESULTS: In vivo, nitroflurbiprofen and flurbiprofen equally decreased portal pressure (8 +/- 0.8 and 8.4 +/- 0.1 mm Hg, respectively, vs 11.8 +/- 0.6 mm Hg) and reduced the total intrahepatic vascular resistance. Systemic hypotension was not aggravated in the different treatment groups (P = .291). In the perfused cirrhotic liver, both drugs improved endothelial dysfunction and hyperresponsiveness. This was associated with a decreased hepatic thromboxane A(2)-production and an increased intrahepatic nitrate/nitrite level. In vitro, nitroflurbiprofen, more than flurbiprofen, decreased hepatic stellate cells contraction. Flurbiprofen-treated rats showed severe gastrointestinal ulcerations (bleeding in 3/8 rats) and nefrotoxicity, which was not observed in nitroflurbiprofen-treated cirrhotic rats. CONCLUSIONS: Treatment with nitroflurbiprofen, an NO-releasing cyclooxygenase inhibitor, improves portal hypertension without major adverse effects in thioacetamide-induced cirrhotic rats by attenuating intrahepatic vascular resistance, endothelial dysfunction, and hepatic hyperreactivity to vasoconstrictors. 相似文献
64.
目的 讨论如何使病人顺利度过化疗反应期。方法通过与病人谈心,解除病人思想顾虑,细心观察化疗过程中病人对MTX的毒性反应,及时给予适当的处理。结果病人可顺利度过化疗毒性反应期。结论熟悉和了解MTX的副反应,加强责任心,认真做好观察护理,及时发现不良反应,并给予适当的处理。 相似文献
65.
66.
Linu A. Jacob Aparna Sreevatsa Lakshmaiah K. Chinnagiriyappa Lokanatha Dasappa T. M. Suresh Govind Babu 《Annals of Indian Academy of Neurology》2015,18(2):206-209
Background:
Intrathecal methotrexate (ITMTX) is an important component in the treatment as well as prophylaxis of leukemia/lymphoma. ITMTX can cause chemical meningitis characterized by vomiting, headache, and fever lasting 2-5 days with spontaneous resolution of symptoms which differentiates this syndrome from bacterial meningitis.Objective:
This prospective observational study was carried out to determine incidence of post-ITMTX syndrome in patients receiving prophylactic ITMTX as part of Berlin-Frankfurt-Munster (BFM) protocol.Materials and Methods:
Patients aged 15-50 years receiving BFM 90 or BFM 95 protocol for acute lymphoblastic leukemia or lymphoblastic lymphoma were followed up for post-ITMTX syndrome, defined as vomiting, headache and fever between 38° and 39°C following ITMTX.Results:
Thirty-three patients received a total of 297 courses of ITMTX. Of the 297 doses of ITMTX, 20 episodes (6.7%) of post-ITMTX syndrome were observed. The incidence of post-ITMTX syndrome was highest after the second dose of ITMTX (24%). The most common symptom of post-ITMTX syndrome was headache which was seen in 17 (85%) patients. Seventeen (85%) patients had vomiting, 10 (50%) patients had fever, and 4 (20%) patients had backache. Meningeal signs were present in 2 (10%) patients.Conclusions:
Post-ITMTX syndrome is not uncommon in adult patients receiving prophylactic ITMTX for treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma. Patients develop a toxic syndrome closely mimicking acute bacterial meningitis but spontaneous recovery is seen without any neurological sequelae. 相似文献67.
大剂量MTX联合化疗淋巴系统恶性肿瘤的临床和药动学研究 总被引:3,自引:0,他引:3
目的:探讨大剂量甲氨蝶呤(HD-MTX3~4g/m^2)连续24小时静脉输注,第36 小时CF解救联合其它化疗药物治疗淋巴系统恶性肿瘤的临床耐受性和药动学研究。方法:分别对11例淋巴系统恶 性肿瘤进行共30个疗程大剂量MTX3~4g/m^2连续24小时静脉输注,第36小时CF解救,同时行血药浓度监测。其中22个疗程HD-MTX在G-CSF支持与其它化疗药物联合应用。结果:一般出现2~3级中性粒细胞减少,1~ 相似文献
68.
Anne C. Bay-Jensen Adam Platt Inger Byrjalsen Philippe Vergnoud Claus Christiansen Morten A. Karsdal 《Seminars in arthritis and rheumatism》2014
Objective
We investigated the effects of tocilizumab (TCZ) on joint tissue remodeling in patients with moderate to severely active RA by measuring tissue-specific biomarker.Methods
The LITHE biomarker study (n = 740) was a phase III study of 4- and 8-mg/kg TCZ in combination with MTX. Early response was evaluated at week 16 as ±20% improvement in swollen/tender joint counts; and ACR50 was evaluated at week 52. Biomarkers (tissue inflammation: C3M, CRPM, and VICM; cartilage degradation: C2M; and bone turnover: CTx and osteocalcin) were tested in serum from baseline, week 4, 16, 24, and 52, and dose-dependent effect was investigated. Patients were divided into the following three groups: early non-responders (ENR), ACR50 responders, and non-responders; their biomarker profiles were compared.Results
At week 52, CRP was inhibited to 4% and 40% of baseline by TCZ8 and TCZ4, respectively. CRPM (63%), C2M (84%), C3M (69%), and VICM (42%) were significantly (p < 0.05) reduced by TCZ8, but not by TCZ4. MMP3 and osteocalcin changed to <58% and >111%, respectively, in response to TCZ. CTx was not changed significantly. ENRs had significantly less inhibition of CRPM (p < 0.05), C2M (p < 0.01), and C3M (p < 0.01) compared to early responders. There was a significant difference in the C2M, C3M, and CRPM profiles of the ENRs, non-responders, and responders. ACR50 responders had significantly inhibited levels (p < 0.001), irrespective of dose.Conclusions
TCZ8 strongly inhibited the biomarkers of joint tissue remodeling suggesting that TCZ actively suppresses key pathobiological processes at the site of inflammation in RA patients. The differences in biomarkers' profiles of responders and non-responders indicate that specific responder profiles exist. 相似文献69.
70.
The uptake of methotrexate (MTX) by isolated rat hepatocytes and its changes under the influence of exogenous GSH have been studied under various conditions: GSH concentration, pH of incubation medium, preincubation of cells prior to MTX and GSH addition, ionic composition of the incubation medium (standard saline, Na+-free, Na+ and K+-free, or ion-deficient), after prior treatment of cells by membrane -SH blockers (p-CMBS, 4-CMB and DIP2+) and ATP.It was found that GSH strongly accelerated MTX uptake. This effect depended on GSH concentration and on preincubation of cells. The GSH effect was not dependent on medium pH in spite of an observed close relationship between pH of incubate and MTX transport itself. Activation by GSH of MTX transport was connected to an increase in intracellular K+. It was also noted that while blockers of membrane -SH groups like p-CMBS and 4-CMB inhibited MTX uptake and increased the intracellular Na+/K+ ratio, both effects were partially overcome by GSH. After treatment by DIP2+, Na+/K+ ratio was unaffected, but MTX uptake inhibited. Still GSH abolished inhibition. Added ATP also inhibited MTX uptake and caused loss of cellular K+ and accumulation of Na+ Here neither effect could be reversed by GSH; consequently, high cellular amounts of K+ and MTX accumulated by previous action of GSH were depleted on subsequent ATP addition. MTX uptake was low in sucrose medium. But in this ion-deficient medium, GSH had the greatest stimulatory effect on MTX uptake.It is concluded that binding GSH can affect the redox state of the -S-S-/-SH groups of the cellular plasma membrane and that this effect of GSH might demonstrate involvement of the redox state in the control of MTX permeability. 相似文献